BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis

BCRX scores 78/100 on Financial Health, which measures profitability, business quality, balance sheet strength, and cash flow. Higher scores reflect stronger compounder characteristics.

Timing looks favorable across trend, momentum, valuation, support, and catalysts. Entry Status is a timing read — separate from business quality.

BCRX has been published 2 times (first Aug 18, 2026, latest Sep 17, 2026). Metrics use an equal-weight average entry of $9.18; the chart starts from the first signal.

Each published signal has its own entry. Return and QQQ are averaged equally across those signals. Alpha is the difference between average return and average QQQ.

No. Compound Radar publishes research models and track records. Do your own research before making investment decisions.

Financial Health scores business quality from profitability, growth, balance sheet, and cash flow. Entry Status is a separate timing read from trend, momentum, valuation, support, and catalysts.

When a setup is published, the entry date and price become the public baseline. Performance is marked to market and compared with QQQ, including wins and losers.

QQQ is a liquid growth-oriented benchmark that fits the kinds of businesses Compound Radar tends to research better than a broad market average alone.